Demonstrates the synthesis and function of a gallium drug to target cancer cells, suggesting its potential as a treatment.
We herein demonstrate that the thiosemicarbazone (TSC) ligand N’-(di(pyridin-2-yl)methylene)-4-(thiazol-2-yl)piperazine-1-carbothiohydrazide (HL) can coordinate with Ga3+ to give cationic complex [Ga(L)2]NO3 featuring an octahedral Ga(III) center. [Ga(L)2]NO3 undergoes metathesis with both Fe2+ and Fe3+, resulting in the formation of respective Fe2+- and Fe3+ complexes. [Ga(L)2]NO3 is also susceptible to anion exchange with sodium hyaluronate (NaA) to produce the nanoformulation [Ga(L)2]A with boosted aqueous solubility and cell targeting. [Ga(L)2]A demonstrated remarkable in vitro cytotoxicity against NCI-H82 and A549 (lung cancer), as well as KYSE-510 and Te-1 (esophageal cancer) cell lines, featuring half maximal inhibitory concentration (IC50) values in the range 0.102–2.616 μmol L−1. This work highlights the potential of using non-toxic and biocompatible Ga3+ as the central ion to prepare TSC-based nanomedicines for combating cancer.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: